GERON CORPORATION

GERN · NASDAQ

Pharmaceutical Preparation Manufacturing

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

ESG Scores

Overall ESG

6.8

Environmental

6.6

Social

4.1

Governance

6.2

Gender Diversity

Female Directors0.5%

Female Executives0.273972602739726%

CEO GenderMale

Market Data

Price$1.56-0.12 (-7.14%)

Market Cap$1.02B

P/E Ratio—

EPS$—

52W High$2.01

52W Low$1.04

Beta0.76